Edwin Taylor, MD
Family Medicine · Milton, FLNPI 1790765915
Payments from drug & device makers
Across 273 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$815
- AbbVie$537
- Pfizer$499
- Novo Nordisk$468
- Lilly USA, LLC$406
- GSK$375
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,517100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $815 |
| AbbVie(2 entities) | 38 | $537 |
| Pfizer | 28 | $499 |
| Novo Nordisk | 26 | $468 |
| Lilly USA, LLC | 26 | $406 |
| GSK | 24 | $375 |
| Amgen | 16 | $246 |
| Bayer | 8 | $185 |
| Exact Sciences | 6 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $90 |
| Cranial Technologies, Inc | 5 | $80 |
| Merck | 5 | $77 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $65 |
| Boehringer Ingelheim | 3 | $58 |
| Abbott | 3 | $45 |
| Johnson & Johnson | 3 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $41 |
| Shield Therapeutics Inc | 2 | $38 |
| Corium, LLC | 1 | $34 |
| Azurity Pharmaceuticals, Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Shire North American Group Inc | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Verona Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Tris Pharma Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$4,517 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $126,879 |
| OzempicSemaglutide | 69 | $114,483 |
| EliquisApixaban | 91 | $112,619 |
| MounjaroTirzepatide | 58 | $91,340 |
| FarxigaDapagliflozin Propanediol | 47 | $50,685 |
| JardianceEmpagliflozin | 28 | $44,994 |
| SymbicortBudesonide/Formoterol Fumarate | 120 | $37,431 |
| TrulicityDulaglutide | 23 | $36,083 |
| LinzessLinaclotide | 41 | $33,119 |
| JanuviaSitagliptin Phosphate | 30 | $31,675 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $21,612 |
| XareltoRivaroxaban | 15 | $20,739 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $14,239 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,407 |
| MyrbetriqMirabegron | 12 | $11,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $375 | $145,800146 claims |
| Lilly USA, LLCMounjaro, Trulicity | $406 | $127,42381 claims |
| PfizerEliquis, Abrysvo | $499 | $117,129105 claims |
| Novo NordiskOzempic | $468 | $114,48369 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $815 | $109,728190 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $58 | $55,62645 claims |
| AbbVieLinzess | $537 | $33,11941 claims |
| MerckJanuvia | $77 | $31,67530 claims |
| Johnson & JohnsonXarelto | $44 | $20,73915 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $11,79012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Milton
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.